Active Ingredient History
Pivalopril (RHC 3659-(S); (S)-N-cyclopentyl-N-(2-methyl-3-pivaloylthiopropionyl) glycine) is an angiotensin-converting enzyme (ACE) inhibitor with antihypertensive activity. Upon hydrolysis, the free SH metabolite of pivopril competitively binds to and inhibits ACE, thereby blocking the conversion of angiotensin I to angiotensin II. This prevents the potent vasoconstrictive actions of angiotensin II and results in vasodilation. Pivopril also decreases angiotensin II-induced aldosterone secretion by the adrenal cortex, which leads to an increase in sodium excretion and subsequently increases water outflow. Pivalopril has been compared to captopril for oral angiotensin-converting enzyme (ACE) inhibition in rats and dogs and antihypertensive activity in rats. In separate groups of conscious normotensive rats, pivalopril (0.03-1.0 mg/kg, orally [p.o.]) produced a dose-related antagonism of angiotensin I (AngI)-induced pressor effects. The ED50 for pivalopriland captopril was 0.1 mg/kg. Pivalopril has being shown to be a potent, orally effective ACE inhibitor and antihypertensive agent. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Combination drugs
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Aortic Valve Stenosis (Phase 4)
Blood Pressure (Early Phase 1)
Cardiotoxicity (Phase 3)
Coronavirus Infections (Phase 2)
COVID-19 (Phase 3)
Diabetes Mellitus (Phase 4)
Diabetes Mellitus, Type 2 (Phase 4)
Drugs, Investigational (Phase 2)
Essential Hypertension (Phase 2)
Glioblastoma (Phase 1)
Healthy Volunteers (Phase 1)
Heart Diseases (Phase 4)
Hemangioma (Phase 4)
Hyperaldosteronism (Phase 4)
Hypertension ()
Hypertension, Pulmonary (Phase 1)
Hypotension (Phase 4)
Inflammation (Phase 4)
Kidney Diseases (Phase 4)
Kidney Failure, Chronic (Phase 4)
Leukemia, Myeloid, Acute (Phase 3)
Lung Diseases (Phase 2)
Lung Neoplasms (Phase 2)
Metabolic Syndrome (Phase 4)
Multiple System Atrophy (Phase 1)
Myeloproliferative Disorders (Phase 2)
Neoplasms (Phase 3)
Peripheral Arterial Disease (Phase 3)
Pneumonia (Phase 2)
Pre-Eclampsia (Phase 4)
Primary Myelofibrosis (Phase 1/Phase 2)
Pure Autonomic Failure (Phase 1)
Radiation Fibrosis Syndrome (Phase 2)
Radiation Pneumonitis (Phase 2)
Renal Insufficiency (Phase 4)
Ventricular Dysfunction, Left (Phase 4)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
